Views & Analysis | Perspectives on pharma industry issues

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

R&D

From phase 1 to phase 3: Scaling radiopharmaceutical trials

Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.

Patients

pharmaphorum podcast Episode 285, Donna Cryer, CryerHealth, LLC

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

R&D

Gravity is an experimental variable pharma has rarely been a...

Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.

Articles

mHealth Monthly Mashup: release 3.0 - the role of non-profi...

Checking in to his next instalment in the series, Michael Spitz teams with Michelle Petersen to discuss how non-profits have shaped the evolution of mHealth and continue to benefit millions throughout the world. The notion that complex problems demand equally complex solutions is endemic throughout...

Articles

Inside view: rising to the challenges of orphan drug develop...

Developing new medicines for rare diseases is a challenging, but rewarding, space for pharma. pharmaphorum talks to Wills Hughes-Wilson, from Genzyme, to find out more. Working in the rare disease space presents a number of challenges for pharma – low patient numbers and lack of disease awareness hinder development...

Articles

Case study: optimizing co-pay program benefit design

Kelly Renfro highlights the impact that out of pocket costs and co-payment programs have on adherence. Much has been written lately about the complexity of medication adherence and the variety of barriers that impact whether or not someone takes their…

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.